TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By The Schall Law Firm
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against aTyr Pharma for allegedly making false and misleading statements about its Phase 3 trial of Efzofitimod, potentially concealing the drug's true capabilities.

Insights
TSLA   neutral

Part of Magnificent Seven with significant market representation


ATYR   negative

The company is accused of making false statements about its drug trial, potentially misleading investors about Efzofitimod's capabilities, which could result in financial damages and legal consequences